07-08-2026 21:55 via medpagetoday.com

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

(MedPage Today) -- Liposomal daunorubicin and cytarabine (Vyxeos) didn't hold up to standard daunorubicin/cytarabine induction therapy in children and young adults with newly diagnosed acute myeloid leukemia (AML), a phase III trial from the Children...
Read more »